Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction

Japanese Circulation Journal

Volumn 62, Issue 2, 1998, Pages 111-114

  Nagao, Ken ^a,b   Satou, Kazuyoshi ^b   Watanabe, Ikuyoshi ^b   Arima, Ken ^b   Yamashita, Makoto ^b   Ooiwa, Koji ^b   Kanmatsuse, Katsuo ^b  

^a NIHON UNIVERSITY   (Japan)

^b SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acute myocardial infarction; Mutant t PA; Thrombolysis; Urokinase

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE;

ACUTE DISEASE; AGED; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MUTATION; MYOCARDIAL INFARCTION; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031906507     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.62.111     Document Type: Article

References (28)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; i: 397-402
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction; ISIS-2. Lancet 1988; ii: 349-360
3. Wilcox RG, Von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; ii: 525-530
4. ISAM Study Group: A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). Mortality, morbidity and infarct size at 21 days. N Engl J Med 1986; 314: 1465-1471
5. AIMS Trial Study Group: Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; i: 842-847
6. Topol EJ: Which thrombolytic agent should one choose. Prog Cardiovasc Dis 1991; 34: 165-178
7. Nagao K, Kanmatsuse K, Kajiwara N: Thrombolytic therapy for acute myocardial infarction - effects, problems and their strategies. Jpn Circ J 1994; 58: 885-893
8. Fibrinolytic Therapy Trialists (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients, Lancet 1994; 343: 311-322
9. Lincoff AM, Topol EJ: The illusion of reperfusion: does anyone achieve optimal rcperfusion during acute myocardial infarction? Circulation 1993;87: 1792-1805
10. Chesbro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al: Thrombolysis in myocardial infarction (TIM) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154
11. The TIMI Study Group: The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985; 312: 932-936
12. Topol EJ, Ciuffo AA, Pearson TA, Dillman J, Builder S, Grossbard E, et al: Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion. J Am Coll Cardiol 1985; 5: 85-91
13. Granger CB, Califf RM, Topol EJ: Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992; 44: 293-325
14. Martin U, Kohler J, Sponer G, Strein K: Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs and non-human primates. Fibrinolysis 1992; 6: 17-25
15. Suzuki S, Saito M, Suzuki H, Kato N, Nagaoka S, Yoshitake H, et al: Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E 6010): a bolus injection of E 6010 has equivalent potency at lysing young and aged canine coronary thrombi. J Cardiovasc Pharmacol 1991; 17: 738-746
16. Katoh M, Suzuki Y, Miyamoto I, Watanabe T, Mori K, Arakawa H, et al: Biochemical and pharmacokinetic properties of YM 866, a novel fibrinolytic agent. Thromb Haemostas 1991; 65: 1993
17. Von Essen R, Neuhaus KI, Markreiter M and the GRECO Study Group: Double bolus of r-PA in the dosage finding. Results of the GRECO II-Study (abstract). Circulation 1992; 84(Suppl II): II-274
18. Kawai C, Hosoda S, Motomiya T, Kimata S, Yui Y, Kodama K, et al: Multicenter trial of novel modified t-PA, E 6010, by iv bolus injection in patients with acute myocardial infarction. Circulation 1992; 86: I-409
19. The GUSTO angiographic investigators: the effects of tissue plasminogen activators, strepotkinase, or both on coronary-artery patency, ventricular function, and survival after myocardial infarction. N Engl J Med 1993; 25: 1615-1622
20. Ashizawa A, Nagao K, Kanmatsusc K, Kajiwara N: Importance of coronary arteriogram of the following day after successful coronary thrombolysis: course of residual stenosis of infarct-related coronary artery thrombolysis. J Jpn Coll Angiol 1994; 34: 541-546
21. Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, et al, and TAMI Study Group: Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989; 80: 1222-1230
22. Grines CL, Nissen SE, Booth DC, Gurley JC, Chelliah N, Wolf R, and the Kentucky Acute Myocardial Infarction Trial (KAMIT) Group: A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Circulation 1991; 84: 540-549
23. Topol EJ, Califf RM, George BS, Kereiakes DJ, Rothbaum D, and TAMI-2 Study Group: Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinasc in patients with acute myocardial infarction (TIMI-2). Circulation 1988; 77: 1100-1107
24. Urokinase and Alteplase in Myocardial Infarction Collaborative Group (URALMI): Combination of urokinase and alteplase in the treatment of myocardial infarction. Coronary Artery Dis 1991; 2: 225-235
25. Grines CL, Nissen SE, Booth DC, Branco MC, Gurley JC, Bennett KA, et al: A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. J Am Coll Cardiol 1989; 14: 573-580
26. Bonnett JL, Bory M, D'Houdain F, Joly P, Juhan I, Djiane P, et al: Association of tissue plasminogen activator and streptokinase in acute myocardial infarction: preliminary data (abstract). Circulation 1989; 80(Suppl II): II-343
27. Granger CB, Kalbfleisch J, Califf R, Woodlief L, Karnash S, and the GUSTO Study Group: The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) pilot study: Combined streptokinase and t-PA (abstract). Circulation 1991; 84(Suppl II): II-573
28. National Heart Attack Alert Program (NHAAP) Coordinating committee, Emergency Department: Rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994; 23: 312-329